{"head":{"slug":"vertex-pharmaceuticals-incorporated","name":"Vertex Pharmaceuticals Inc","symbol":"VRTX","sector":"Healthcare","overallScore":5.5,"overallClassification":"HOLD","displayName":"Vertex Pharmaceuticals Inc"},"scores":[{"classification":"HOLD","strategyName":"Wachstums-Momentum (CAN-SLIM-Prinzip)","strategySlug":"wachstums-momentum"},{"classification":"HOLD","strategyName":"Mohanram G-Score: Wachstums-Qualität","strategySlug":"wachstums-qualitaet-g-score"},{"classification":"HOLD","strategyName":"StockScorer-Score","strategySlug":"stockscorer-score"},{"classification":"BUY","strategyName":"Burggraben-Qualität","strategySlug":"burggraben-qualitaet"},{"classification":"SELL","strategyName":"Piotroski F-Score (9-Punkte-Bilanzcheck)","strategySlug":"finanzielle-gesundheit"},{"classification":"BUY","strategyName":"Altman Z-Score: Bilanz-Stresstest","strategySlug":"bilanz-stresstest-z-score"}],"radar":{"categories":["profitability","growth","valuation","momentum"],"median":[33.3,0,0,0],"values":[100,0,0,100]},"peers":[{"classification":"SELL","displayName":"Moderna Inc","locked":false,"name":"Moderna Inc","overallScore":0.9,"slug":"moderna-inc","symbol":"MRNA"},{"classification":"HOLD","displayName":"Regeneron Pharmaceuticals Inc","locked":false,"name":"Regeneron Pharmaceuticals Inc","overallScore":5.5,"slug":"regeneron-pharmaceuticals-inc","symbol":"REGN"},{"classification":null,"displayName":"Revolution Medicines Inc","locked":true,"name":"Revolution Medicines Inc","overallScore":null,"slug":"revolution-medicines-inc","symbol":"RVMD"},{"classification":null,"displayName":"Royalty Pharma Plc","locked":true,"name":"Royalty Pharma Plc","overallScore":null,"slug":"royalty-pharma-plc","symbol":"RPRX"},{"classification":null,"displayName":"CSL Ltd","locked":true,"name":"CSL Ltd","overallScore":null,"slug":"csl-limited","symbol":"CSL.AX"}],"metrics":{"current_ratio":2.9009116336890086,"dividend_growth":null,"dividend_payout_ratio":0,"dividend_streak_years":null,"dividend_yield":0,"dte":0.20800072860525667,"earnings_growth_3y":6.120418790349813,"equity_ratio":71.3993910369203,"ev_ebit":28.85579036885237,"fcf_margin":26.450565650207874,"fcf_yield":2.279618967474573,"kbv":7.561916446120714,"kgv":35.70505413336032,"one_yr":21.826621439466585,"peg":4.31336367562961,"revenue_growth":9.568878685311377,"roc_greenblatt":45.67582607360786,"roe":21.178840446163573},"quote":{"currency":"USD","exchange":"NASDAQ","marketCap":140102361208.99548,"marketCapEur":125727858469.34412,"price":547.09,"priceAsOf":"2026-11-06"},"sectorMedians":{"current_ratio":1.5836203666775437,"dividend_growth":5.623306233062331,"dividend_payout_ratio":35.91314413087717,"dividend_streak_years":10,"dividend_yield":1.3483331598261532,"dte":0.4838372886800787,"earnings_growth_3y":5.440658922332009,"equity_ratio":48.4008953898299,"ev_ebit":21.726364951966808,"fcf_margin":14.117834756719867,"fcf_yield":3.629326385869834,"kbv":4.751254808572999,"kgv":29.969658033759437,"one_yr":8.663206112670974,"peg":1.5047753142982023,"revenue_growth":8.039862019201006,"roc_greenblatt":32.54750002450021,"roe":11.52412853150564},"sectorPercentiles":{"current_ratio":79,"dividend_growth":null,"dividend_payout_ratio":10,"dividend_streak_years":null,"dividend_yield":9,"dte":29,"earnings_growth_3y":53,"equity_ratio":81,"ev_ebit":69,"fcf_margin":87,"fcf_yield":26,"kbv":75,"kgv":60,"one_yr":69,"peg":81,"revenue_growth":59,"roc_greenblatt":66,"roe":79},"sectorProfile":{"radar":{"categories":["profitability","growth","valuation","momentum","quality","risk"],"median":[50,50,50,50,50,50],"values":[83.6,53.9,28.8,63.1,28.9,73.6]},"sectorRank":55.3,"strongest":"profitability","weakest":"valuation"},"flagshipRules":[{"id":"ss-31","knockout":false,"points":2,"status":"unmet"},{"id":"ss-32","knockout":false,"points":2,"status":"met"},{"id":"ss-33","knockout":false,"points":1,"status":"met"},{"id":"ss-34","knockout":false,"points":2,"status":"met"},{"id":"ss-27","knockout":false,"points":2,"status":"unmet"},{"id":"ss-28","knockout":false,"points":1,"status":"unmet"},{"id":"ss-29","knockout":false,"points":1,"status":"met"},{"id":"ss-30","knockout":false,"points":0,"status":"unmet"}],"strategyLockedNames":[{"strategyName":"Ertragsqualität: Accrual-Check (Sloan)","strategySlug":"ertragsqualitaet-accrual-check"},{"strategyName":"Levermann-Strategie (13 Kriterien)","strategySlug":"13-kriterien-punktesystem"},{"strategyName":"Magic Formula: Value + Qualität","strategySlug":"qualitaet-value"},{"strategyName":"Defensiv: Low Volatility","strategySlug":"defensiv-low-volatility"},{"strategyName":"Unterbewertete Aktien: Mehrfaktor-Check","strategySlug":"unterbewertung-mehrfaktor"},{"strategyName":"High-Growth / Rule of 40","strategySlug":"high-growth-rule-of-40"},{"strategyName":"Acquirer's Multiple: EV/EBIT Deep Value","strategySlug":"ev-ebit-deep-value"},{"strategyName":"Dividenden-Aristokraten & Kontinuität","strategySlug":"dividenden-kontinuitaet"},{"strategyName":"Dividenden-Qualität: 4 Faktoren","strategySlug":"dividenden-qualitaet"},{"strategyName":"GARP Ausgewogen","strategySlug":"garp-ausgewogen"},{"strategyName":"PEG-Strategie nach Peter Lynch","strategySlug":"peg-strategie"},{"strategyName":"Trending Value: Value + Momentum","strategySlug":"value-momentum"}],"company":{"description":"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.","industry":"Biotechnology","ipoDate":"1991-07-24"},"sectorBreakdown":{"growth":{"metrics":[{"counts":true,"field":"revenue_growth","lowerIsBetter":false,"rank":59.1,"sectorMedian":8.039862019201006,"value":9.568878685311377},{"counts":true,"field":"earnings_growth_3y","lowerIsBetter":false,"rank":52.7,"sectorMedian":5.440658922332009,"value":6.120418790349813},{"counts":true,"field":"earnings_growth_5y","lowerIsBetter":false,"rank":54.9,"sectorMedian":7.003389122494063,"value":8.27777503090985},{"counts":true,"field":"sus_growth","lowerIsBetter":false,"rank":48.9,"sectorMedian":3.6635701466492088,"value":3.6241366173620655}],"value":53.9},"momentum":{"metrics":[{"counts":true,"field":"one_yr","lowerIsBetter":false,"rank":69.4,"sectorMedian":8.663206112670974,"value":21.826621439466585},{"counts":true,"field":"six_m","lowerIsBetter":false,"rank":59.4,"sectorMedian":24.27032259851255,"value":27.766966979686693},{"counts":true,"field":"three_m","lowerIsBetter":false,"rank":50,"sectorMedian":15.416211475410979,"value":15.416211475410979},{"counts":true,"field":"pct_from_52w_high","lowerIsBetter":false,"rank":73.7,"sectorMedian":-7.345407316545205,"value":-2.1095762954480346}],"value":63.1},"profitability":{"metrics":[{"counts":true,"field":"roe","lowerIsBetter":false,"rank":79.5,"sectorMedian":11.52412853150564,"value":21.178840446163573},{"counts":true,"field":"roc_greenblatt","lowerIsBetter":false,"rank":66.3,"sectorMedian":32.54750002450021,"value":45.67582607360786},{"counts":true,"field":"ebit_margin","lowerIsBetter":false,"rank":93.8,"sectorMedian":18.305086092796074,"value":39.42739303993507},{"counts":true,"field":"fcf_margin","lowerIsBetter":false,"rank":87.1,"sectorMedian":14.117834756719867,"value":26.450565650207874},{"counts":true,"field":"gross_margin","lowerIsBetter":false,"rank":91.5,"sectorMedian":60.99422024571629,"value":85.03387275768969}],"value":83.6},"quality":{"metrics":[{"counts":true,"field":"sloan_ratio","lowerIsBetter":true,"rank":17.6,"sectorMedian":0.2985136689791994,"value":5.20667269290821},{"counts":true,"field":"share_change","lowerIsBetter":true,"rank":34.9,"sectorMedian":-0.002392665312306813,"value":0.038774718883288095},{"counts":true,"field":"dividend_streak_years","lowerIsBetter":false,"rank":12.9,"sectorMedian":10,"value":null},{"counts":true,"field":"reaction_rel","lowerIsBetter":false,"rank":50,"sectorMedian":0.05056951189927883,"value":0.05056951189927883}],"value":28.9},"risk":{"metrics":[{"counts":true,"field":"equity_ratio","lowerIsBetter":false,"rank":80.9,"sectorMedian":48.4008953898299,"value":71.3993910369203},{"counts":true,"field":"debt_to_ebitda","lowerIsBetter":true,"rank":77.5,"sectorMedian":1.1117596945697787,"value":-0.5607134784127571},{"counts":true,"field":"dte","lowerIsBetter":true,"rank":70.7,"sectorMedian":0.4838372886800787,"value":0.20800072860525667},{"counts":true,"field":"volatility_1y","lowerIsBetter":true,"rank":65.1,"sectorMedian":31.42353880746313,"value":29.335628569763678}],"value":73.6},"valuation":{"metrics":[{"counts":true,"field":"earnings_yield","lowerIsBetter":false,"rank":46.4,"sectorMedian":2.8966594312400864,"value":2.8007239430724447},{"counts":true,"field":"fcf_yield","lowerIsBetter":false,"rank":25.5,"sectorMedian":3.629326385869834,"value":2.279618967474573},{"counts":true,"field":"ev_to_sales","lowerIsBetter":true,"rank":12,"sectorMedian":4.026437265234489,"value":11.377085883507155},{"counts":true,"field":"ev_ebit","lowerIsBetter":true,"rank":31.4,"sectorMedian":21.726364951966808,"value":28.85579036885237}],"value":28.8}},"expectation":{"inputs":{"basis":"fcf","capex":null,"capexDepressed":false,"fcf":3193800000,"fcfBasis":"fy","fcfNormalized":null,"fcfWindowEnd":null,"fcfYear":2025,"kbv":7.561916446120714,"marketCap":140102361208.99548,"marks":{"fiveYear":-15.23,"tenYear":41.46}},"standard":{"basis":"fcf","case":"betweenMarks","discountRate":9,"noGrowthValue":35486666666.66667,"value":19.132052782470055,"years":10},"standardNormalized":null},"quarterChanges":{"case":"mostlyBetter","changes":[{"change":-18.81,"current":-4165900000,"direction":"better","metric":"netDebt","previous":-3506400000,"signChange":false,"unit":"percent"}],"current":{"quarter":2,"year":2026},"previous":{"quarter":1,"year":2026},"unchanged":["revenue","fcf","grossMargin","ebitMargin","fcfMargin","sharesOutstanding","roe"]},"evidence":{"anomalies":[{"key":"volatile_earnings","value":4}],"contra":["volatile_earnings"],"moat":[{"holds":true,"key":"stableGrossMargin","median":87.42,"spread":3.92,"years":10},{"first":88.06,"holds":false,"key":"risingGrossMargin","last":85.03,"years":5},{"holds":false,"key":"highReturnOnCapital","min":-1.23,"years":10},{"holds":true,"key":"lowCapitalIntensity","median":3.12,"years":10},{"holds":false,"key":"steadyFcfMargin","min":-7.17,"spread":55.41,"years":10}],"phase":{"ebitMargin":39.4,"financingCf":-2261300000,"investingCf":-945400000,"key":"scaling","operatingCf":3631400000,"payoutShare":55.6,"revenueCagr3y":10.6,"revenueGrowthYoy":null},"pro":["stableGrossMargin","lowCapitalIntensity"]},"valuationBand":{"anchor":{"quarter":2,"year":2026},"high":28.2,"low":20.5,"median":23.8,"metric":"priceToOcf","multiple":32.6,"position":"above","priceAsOf":"2026-11-06","quarters":16}}